Dell Inc. Signs Reseller Agreement with WordLogic Corp. and other news
On March 28, 2011, we issued an Executive Informational Overview (EIO) on WordLogic Corp. (WLGC-OTCBB). ...
M&A activity on the rise for 2011
From January through November 2010, there were over 21,000 mergers and acquisitions (M&A) agreements ...
Recent Financial Results and Updates
Last week, several companies within our coverage universe released financial results and corporate updates, ...
Large Pharma Increasing Investment in Emerging Countries
Yesterday morning, Sanofi-Aventis SA (SNY-NYSE) released its 2010 financial results. Among other news, the ...
A Solid Start to 2011
As we kick off the New Year, many companies within our Coverage Universe are showing a positive start to ...
Both Sides of the Fence for 2011
We hope everyone had an enjoyable and safe December, with happy, relaxing holidays. As 2011 approaches, a ...
Mid-Week News Highlights (12/6-12/8) from CRA’s Coverage Universe
News from our coverage universe this week includes Johnson & Johnson’s bid to buy Crucell for $2.3 ...
Unilife Reports Financial Results and Significant Milestones
Unilife Corp. (UNIS-NASDAQ) has recently announced its financial results for the three months ended September ...
Up to $1 Billion in New Credits/Grants for Healthcare
As part of the Patient Protection and Affordable Care Act of 2010, Congress established a program known as ...
Recent Financial Results and Corporate Updates
Several companies within our Research Library this week reported financial results, including ...
Bioniche Named Among Top Employers in Canada
Today, Bioniche Life Sciences Inc. (BNC-TSX), a research-based, technology-driven Canadian biopharmaceutical ...
Promising Clinical Events from Neuralstem and Peregrine
Neuralstem, Inc. (CUR-NYSE Amex) announced on Monday of this week that it would begin enrolling the next ...
Corporate Update from TapImmune and Positive Phase II Data from ACT Biotech
TapImmune Inc. (TPIV-OTC.BB), a developer of immunotherapeutics for cancer and infectious disease, yesterday ...
CEL-SCI’s progress toward the start of its Phase III trial
CEL-SCI Corporation (CVM-NYSE Amex) is advancing its Phase III clinical trial of Multikine®, CEL-SCI’s lead ...